Your browser doesn't support javascript.
loading
CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes.
Onodera, Taishi; Sax, Nicolas; Sato, Takashi; Adachi, Yu; Kotaki, Ryutaro; Inoue, Takeshi; Shinnakasu, Ryo; Nakagawa, Takayuki; Fukushi, Shuetsu; Terooatea, Tommy; Yoshikawa, Mai; Tonouchi, Keisuke; Nagakura, Takaki; Moriyama, Saya; Matsumura, Takayuki; Isogawa, Masanori; Terahara, Kazutaka; Takano, Tomohiro; Sun, Lin; Nishiyama, Ayae; Omoto, Shinnya; Shinkai, Masaharu; Kurosaki, Tomohiro; Yamashita, Kazuo; Takahashi, Yoshimasa.
Afiliação
  • Onodera T; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Sax N; KOTAI Biotechnologies Inc., Osaka, Japan.
  • Sato T; Tokyo Shinagawa Hospital, Tokyo, Japan.
  • Adachi Y; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Kotaki R; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Inoue T; Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan.
  • Shinnakasu R; Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan.
  • Nakagawa T; Shionogi & Co. Ltd., Osaka, Japan.
  • Fukushi S; Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan.
  • Terooatea T; KOTAI Biotechnologies Inc., Osaka, Japan.
  • Yoshikawa M; Shionogi & Co. Ltd., Osaka, Japan.
  • Tonouchi K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Nagakura T; Department of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan.
  • Moriyama S; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Matsumura T; Laboratory of Viral Infection, Omura Satoshi Memorial Institute Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan.
  • Isogawa M; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Terahara K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Takano T; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Sun L; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Nishiyama A; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Omoto S; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Shinkai M; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Kurosaki T; Shionogi & Co. Ltd., Osaka, Japan.
  • Yamashita K; Tokyo Shinagawa Hospital, Tokyo, Japan.
  • Takahashi Y; Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan.
Sci Adv ; 9(24): eadf0661, 2023 06 16.
Article em En | MEDLINE | ID: mdl-37315144
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Subpopulações de Linfócitos B / Selectina L / COVID-19 Limite: Humans Idioma: En Revista: Sci Adv Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Subpopulações de Linfócitos B / Selectina L / COVID-19 Limite: Humans Idioma: En Revista: Sci Adv Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão